BOSTON — April 16, 2026 — Kailera Therapeutics, Inc. (Nasdaq: KLRA) (“Kailera”), an advanced clinical-stage biotechnology company developing next-generation treatments for obesity, today announced the pricing of its initial public offering (IPO) of 39,062,500 shares of common stock at $16.00 per share. All shares in the offering are being sold by Kailera.
Gross proceeds to Kailera from the offering are expected to be $625.0 million, prior to deducting underwriting discounts, commissions, and offering expenses.
Key IPO Details
-
Ticker Symbol: KLRA (Nasdaq Global Select Market)
-
Offer Price: $16.00 per share
-
Shares Offered: 39,062,500 shares of common stock
-
Expected Trading Date: April 17, 2026
-
Expected Closing Date: April 20, 2026, subject to customary closing conditions
-
Over-Allotment Option: 30-day option for underwriters to purchase up to an additional 5,859,375 shares at the initial public offering price, less underwriting discounts and commissions.
A registration statement on Form S-1 (File No. 333-294690) relating to the offering has been filed with the Securities and Exchange Commission and became effective on April 16, 2026. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at [email protected] and [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected].
This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contact
Maura Gavaghan
Vice President, Corporate Communications and Investor Relations
[email protected]

